Rahila Angelova Mbal AD — Clinical Trial Site

9 Registered trials

6 Currently recruiting

Organisation

Rahila Angelova Mbal AD

Location

Pernik, Bulgaria

Identifier

ORG-100047905

Address

Ulitsa Breznik 2, 2300, Bulgaria

Departments

First Internal Department
First internal department - internal diseases II level internal diseases II level
Hemodialysis department
Internal Medicine

Clinical trials at this site (9)

Search interface

The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting

2024-518589-29-00 Bronchiectasis 5 2025-08-21
A Phase IIb study to evaluate the effect of combination of dapagliflozin and baxdrostat compared with baxdrostat alone in participants with … Recruiting

2025-522407-23-00 Chronic kidney disease (CKD) and hypertension. 4 2026-04-16
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients with Coronavirus Disease 2019 (COVID-19) who ar… Recruiting

2024-517727-39-00 Covid-19 at high risk of progression to severe illness. 5 2025-07-28
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma Ended

2024-519469-23-00 Severe Asthma 4 2025-10-20
A study to investigate the effect on lung function of an approved COPD treatment (BGF, with HFA propellant) compared to BGF formulated with… Ended

2023-506565-57-00 Moderate to Severe Chronic Obstructive Pulmonary Diseas 5 2024-06-21
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT) Ended

2023-507410-27-00 Severe Asthma 4 2024-06-19